Form D · Pharmaceuticals
CeleCor Therapeutics, Inc.
Del Mar, CA · CIK 0001705381
Offering snapshot reported Jul 9, 2026 · SEC filing
- Reported sold
- $11.9M Offering amount: $15M
- Investors reported
- 17 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 9, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 9, 2026 | Initial | $11,856,325 | No comparison | 17 | SEC filing |
| Aug 21, 2024 | Amendment | $45,500,000 | $27,750,000vs Aug 3, 2023 | 11 | SEC filing |
| Aug 3, 2023 | Amendment | $17,750,000 | $15,050,000vs Mar 8, 2022 | 11 | SEC filing |
| Mar 8, 2022 | Initial | $2,700,000 | No comparison | 4 | SEC filing |
| May 10, 2021 | Initial | $1,000,000 | No comparison | 1 | SEC filing |
| May 3, 2017 | Initial | $0 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-590216
Source: Form D, filed Jul 9, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Peter B. Finn | Executive |
| Robert Hillman | Director, Executive |
| Robert S. Hillman, Ph.D. | Director, Executive |
| Jack Lief | Director |
| Andreas Ritzi | Director |
| Caspar F.V. Sturm | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1155 Camino Del Mar Suite 481
Del Mar, CA, 92014
Del Mar, CA, 92014